-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 19th, Drug Network announced its 2020 Q3 results.
financial results show that 1 pharmaceutical network Q3 recorded a single quarter of revenue, net revenue of 2.36 billion yuan (RMB, the same as 112.8 percent), up 112.8 percent year-on-year;
At the same time, the Company's cash flow performance continued to be good, with cash and cash equivalents, restricted cash and short-term investments totalling $1,213 million as of September 30, 2020, resulting in positive cash flow of $25 million from operating activities in the quarter.
Digital Technology strengthens the commercialization capability of 1 drug network Q3 revenue increased by 112.8% YoY According to Q3 financial report, 1 drug online market has achieved nearly 100% revenue growth for 8 consecutive quarters;
Q3 results showed that the B2B business of 1 pharmaceutical network achieved 1.114 million orders for pharmacies, up 297 percent year-on-year, revenue of 2.202 billion yuan, up 134.1 percent year-on-year, and gross profit of 558 million yuan, up 344.5 percent year-on-year.
On the one hand, 1 drug network through innovative intelligent supply chain technology, Q3 tracking cost ratio fell to 2.5%, the lowest after the market;
note: There are deletions in the original text
